Thredd Launches First-to-Market Fraud Solution in Collaboration with Featurespace
8.10.2025 09:00:00 CEST | Business Wire | Press Release
Thredd, a leading next-generation global payments processor, today announced the introduction of One View, a first-to-market fraud solution developed in collaboration with global fraud and financial crime detection innovators, Featurespace, a Visa solution. The solution enables card transactions and non-card payments to be intelligently monitored under one, network-agnostic interface and rules engine to boost fraud detection.
One View was developed to bring together card and non-card payment data, like account-to-account (A2A) payments and person-to-person (P2P) payments, into a single interface, providing a 360° view of customer behavior and enabling more effective fraud detection while reducing related workloads.
According to the companies, the solution eliminates the need for fraud analysts to log into separate systems for cards and payments. Instead, fraud teams get a unified interface with consistent workflows and logic, streamlining investigation, reducing toggling, and cutting resolution times - ultimately leading to better coverage with less strain on internal resources.
“For the first time, FinTechs, banks and other organizations involved in payments processing can benefit from streamlined processes which enable them to fully utilize payment data to boost fraud detection and make the world a safer place to transact,” said Jason Blackhurst, Global Head of Featurespace and Acceptance Risk Solutions at Visa. “Clients choosing the new solution also benefit from Thredd’s differentiated expertise and in-house services in integrating and optimizing the solution,” he added.
"Now fraud teams can spot unusual behavior patterns that might not be flagged in isolated systems, and choose to equip themselves with self-resolving alerts that can be sent directly to customers, enabling them to approve or decline transactions themselves," said Anthony Gudgeon, Head of Fraud Operations of Thredd. “As a result, clients reduce their customer service workload and can eliminate the need for 24/7 manual monitoring,” he said.
According to Thredd and Featurespace, the API-first, plug-and-play solution allows clients to go live quickly and see immediate value without upfront training. In addition, the solution can be deployed to replace legacy fraud solutions or as an augmentation layer across both cards and payments, balancing fraud detection with customer experience, helping to minimise false positives and improve detection rates.
Featurespace provides groundbreaking solutions using AI and machine learning to help banks and financial institutions crack down on fraud. Featurespace’s ARIC™ Risk Hub adapts in real-time to accurately identify abnormal behavior, minimize errors and locate them at speed. Since Featurespace’s inception at the University of Cambridge in 2008, the company’s technology has helped protect more than 500 million consumers globally in over 100 countries.
About Thredd
Thredd is the trusted next-generation payments processing partner for innovators looking to modernise their payments offerings worldwide. We process billions of debit, prepaid and credit transactions annually, serving over 100 fintechs, digital banks, and embedded finance providers, from consumer to corporate, based across 47 countries. Learn more at https://www.thredd.com
About Featurespace
Featurespace, a Visa Solution, is a global, AI-native transaction monitoring company that helps to prevent fraud and financial crime. Using artificial intelligence, it analyses data in real time to identify and stop existing and new forms of fraud and financial crime.
Delivering on its mission to make the world a safer place to transact, Featurespace works with many of the world’s largest banks and financial institutions, protecting 500 million consumers globally and safely processing over 100 billion payment events each year.
Over 100,000 businesses put their trust in Featurespace’s technology including NatWest, TSYS, Worldpay, Danske Bank, Akbank and Edenred. Founded in 2008, and headquartered in Cambridge, UK, Featurespace has more than 400 team members, operating globally from six locations. Learn more at featurespace.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251008524422/en/
Contacts
Simeon Lando
Chief Marketing Officer
press@thredd.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom